Our study demonstrates that hs-cTnI has the greatest impact when predicting the risk of MACE, CV mortality, and all-cause mortality in patients with HD, surpassing established risk markers such as BNP, age, previous CV events, hypertension, dyslipidaemia, diabetes mellitus, and smoking. The gene discussed is TNNI3; the disease is inherited lipid metabolism disorder.